CHEMOMAB THERAPEUTICS LTD DRC reports a Return on Equity (ROE) of -69.72%.

What is CMMB's dividend yield?

CHEMOMAB THERAPEUTICS LTD DRC offers a dividend yield of 0.00%.

What is CMMB's Quality Score?

Our AI rates CMMB's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CMMB?

Our AI Timing Score for CMMB is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CMMB belong to?

CHEMOMAB THERAPEUTICS LTD DRC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

CMMB (NASDAQ) Stock Analysis | CHEMOMAB THERAPEUTICS LTD DRC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

CMMB AI Analysis Summary

Our AI summary for CMMB: CHEMOMAB THERAPEUTICS LTD DRC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -69.72%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CMMB

CHEMOMAB THERAPEUTICS LTD DRC

US:NASDAQ STOCK Healthcare >> Biotechnology News 98

USD 1.55

0.02 (1.31%) Day Change

Watchlist Portfolio Compare Chart

0.10

D/E

-69.7%

ROE

-63.2%

ROA

0.00%

Div Yield

CHEMOMAB THERAPEUTICS LTD DRC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.55 Price 0.02 (1.31%) Day Change	NEWS SCORE: 98

CMMB, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.55
PBV / Sector	1.05 / 5.20 GREAT
Earning Per Share	-1.03

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	0.44 M GREAT
Average 1W Daily Value	0.10 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	N/A / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-63.15 / 27.02
ROA Average (%) / Sector	-76.80 / -368.17
ROA Change Average (%) / Sector	5.42 / 5,404.12
ROE (%) / Sector	-69.72 / 3.47
ROE Average (%) / Sector	-92.90 / 6.51
ROE Change Average (%) / Sector	6.35 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:39
Symbol	CMMB
Name	CHEMOMAB THERAPEUTICS LTD DRC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	7.33 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	11.21 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Building C, Tel Aviv-Yafo, Israel, 6158101

Phone: 972 77 331 0156

Website: https://www.chemomab.com

Sector: Healthcare >> Biotechnology

Description: Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.